Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 5/2000

01-11-2000 | Review Article

Skin Cancer Risk Associated with Immunosuppressive Therapy in Organ Transplant Recipients

Epidemiology and Proposed Mechanisms

Authors: Iris Kuijken, Jan N. Bouwes Bavinck

Published in: BioDrugs | Issue 5/2000

Login to get access

Abstract

The aim of this review is to summarise the available literature regarding the epidemiology and proposed mechanisms of skin cancer development in organ transplant recipients who are receiving lifelong treatment with immunosuppressive therapy and to review the different strategies for managing complications in this group of patients.
Organ transplantation is complicated by an increased incidence of certain cancers, of which non-Hodgkin’s lymphoma, Kaposi’s sarcoma and squamous cell carcinoma are the most common. The most important risk factor for these cancers is immunosuppressive therapy. The relative importance of different immunosuppressive therapy regimens in relation to the development of skin cancer is still unclear. Immunosuppression per se may play the most important role, but other mechanisms, which are independent of host immunity and which may be different for the various agents used, may also be of importance for the increased risk of cancer.
Apart from immunosuppressive therapy, exposure to sunlight and infection with human papillomaviruses are believed to be the most important risk factors for the development of cutaneous squamous cell carcinoma in organ transplant recipients. Human papillomaviruses, no doubt, benefit considerably from immunosuppression, as is indicated by the large number of warts found in these patients, but many questions remain unanswered about their significance in cutaneous oncogenesis. The E6 protein from a range of cutaneous human papillomavirus types effectively inhibits apoptosis in response to ultraviolet light damage. It is, therefore, conceivable that the development of skin cancer in organ transplant recipients is the result of a complex interplay between exposure to ultraviolet radiation, human papillomavirus infection and genetic predisposition.
Measures for protection from the sun are important for reducing the risk of skin cancer in organ transplant recipients. Regular surveillance of patients with skin problems and easy access to a dermatologist for these patients is advised. Changing the immunosuppressive regimen from azathioprine to cyclosporin or vice versa does not seem to relieve the skin problems. Tapering the immunosuppressive therapy to the lowest possible dose may be of some advantage. Oral retinoids, e.g. acitretin, have some effect in reducing the number of keratotic skin lesions and in the prevention of skin cancer in organ transplant recipients. Resurfacing the back of the hand can be a successful treatment for patients with multiple skin cancers on the back of the hand and can be used prophylactically in patients with severely actinically damaged skin.
Literature
1.
Boyle J, MacKie RM, Briggs JD, et al. Cancer, warts, and sunshine in renal transplant recipients: a case-control study. Lancet 1984; I: 702–5CrossRef
2.
Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, et al. Relation between skin cancer and HLA antigens in renaltransplant recipients. N Engl J Med 1991; 325: 843–8CrossRef
3.
Bouwes Bavinck JN, Vermeer BJ, Claas FHJ, et al. Skin cancer and renal transplantation. J Nephrol 1994; 7: 261–7
4.
Penn I, Branson ME. Cancers after cyclosporine therapy. Transplant Proc 1988; 20 Suppl. 3: 885–92PubMed
5.
Bouwes Bavinck JN, van Zuuren EJ, ter Schegget J. Cutaneous warts and carcinomas. In: Euvrard S, Kanitakis J, Claudy A, editors. Skin diseases after organ transplantation. Paris: John Libbey Eurotext, 1998: 122–30
6.
Bouwes Bavinck JN, Berkhout RJM. HPV infections and immunosuppression. Clin Dermatol 1997; 15: 427–37CrossRef
7.
Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177–86PubMedCrossRef
8.
Opeltz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–6CrossRef
9.
Mueller N. Overview of the epidemiology of malignancy in immune deficiency. J Acquir Immune Defic Syndr 1999; 21 Suppl. l:S5–10PubMed
10.
Penn I, First MR. Merkel’s cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999; 68 (11): 1717–21PubMedCrossRef
11.
12.
Hartevelt MM, Bouwes Bavinck JN, Kootte AMM, et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506–9PubMedCrossRef
13.
Barr BBB, Benton EC, McLaren K, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989; I: 124–9CrossRef
14.
Hardie IR. Skin cancer in transplant recipients. Transplant Rev 1995; 9: 1–17CrossRef
15.
Cathomas G. Human herpes virus 8: a new virus discloses its face. Virchows Arch 2000; 436 (3): 195–206PubMedCrossRef
16.
Szende B, Toth A, Perner F, et al. Clinicopathologic aspects of 8 Kaposi’s sarcomas among 1009 renal transplant patients. Gen Diagn Pathol 1997; 143 (4): 209–13PubMed
17.
Farge D, Lebbe C, Marjanovic Z, et al. Human herpes virus-8 and other risk factors for Kaposi’s sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d’ Ile de France (GCIF). Transplantation 1999; 67 (9): 1236–42PubMedCrossRef
18.
Ecder ST, Sever MS, Yildiz A, et al. Kaposi’s sarcoma after renal transplantation in Turkey. Clin Transplant 1998; 12 (5): 472–5PubMed
19.
Perna AM, Bonura F, Vitale F, et al. Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily. Int J Epidemiol 2000; 29 (1): 175–9PubMedCrossRef
20.
Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi’s sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation 1999; 67 (1): 180–4PubMedCrossRef
21.
Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61: 715–21CrossRef
22.
Greene MH, Young TI, Clark WH. Malignant melanoma in renal transplant recipients. Lancet 1981; I: 1196–9CrossRef
23.
Green A, Siskind V, Green L. The incidence of melanocytic naevi in adolescent children in Queensland, Australia. Melanoma Res 1995; 5: 155–60PubMedCrossRef
24.
Garbe C, Büttner P, Weiβ J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German dermatological society. J Invest Dermatol 1994; 102: 695–9PubMedCrossRef
25.
Barker JNWN, MacDonald DM. Eruptive dysplastic nevi following renal transplantation. Clin Exp Dermatol 1988; 13: 123–5PubMedCrossRef
26.
Smith CH, McGregor JM, Barker JNWN, et al. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993; 28: 51–5PubMedCrossRef
27.
Szepietowski J, Wasik F, Szepietowski T, et al. Excess benign melanocytic naevi in renal transplant recipients. Dermatology 1997; 194: 17–9PubMedCrossRef
28.
Bouwes Bavinck JN, Crijns M, Vermeer BJ, et al. Chronic sun exposure and age are inversely associated with nevi in adult renal transplant recipients. J Invest Dermatol 1996; 106: 1036–41CrossRef
29.
Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatim and squamous neoplasia of the cervix. Acta Cytol 1983; 27: 220–4PubMed
30.
Alloub MI, Barr BBB, McLaren KM, et al. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989; 298: 153–6PubMedCrossRef
31.
Kelly GE, Sheil AGR, Rose BR, et al. HPV infection in the lower genital tract of women undergoing hemodialysis and women with renal allografts. Clin Transplant 1991; 5: 7–12
32.
International Agency for Research on Cancer. Human papillomaviruses. Lyon: IARC Scientific Publications; 1995
33.
Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ-transplant recipients: a clinicopathologic and virologic assessment. Arch Dermatol 1996; 133 (2): 175–8CrossRef
34.
Fairley CK, Sheil AGR, McNeil JJ, et al. The risk of ano-genital malignancies in dialysis and transplant patients. Clin Nephrol 1994; 41: 101–5PubMed
35.
Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the nordic countries. Int J Cancer 1995; 60: 183–9PubMedCrossRef
36.
King GN, Healy CM, Dent B, et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 1995; 332: 1052–7PubMedCrossRef
37.
van Zuuren EJ, de Visscher JGAM, Bouwes Bavinck JN. Carcinoma of the lip in kidney transplant recipients. J Am Acad Dermatol 1998; 38: 497–9PubMedCrossRef
38.
Hardie IR, Strong RW, Hartley LCJ, et al. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980; 87: 177–83PubMed
39.
Glover MT, Niranjan N, Kwan JTC, et al. Non-melanoma skin cancer in renal transplant recipients: extent of the problem and a strategy for management. Br J Plast Surg 1994; 47: 86–9PubMedCrossRef
40.
London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403–6PubMedCrossRef
41.
Ferrándiz C, Fuente MJ, Ribera M, et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995; 33: 590–6PubMedCrossRef
42.
Lampros TD, Cobanoglu A, Parker F, et al. Squamous and basai cell carcinoma in heart transplant recipients. J Heart Lung Transplant 1998; 17 (6): 586–91PubMed
43.
Ong CS, Keogh AM, Kossard S, et al. Skin cancer in Australian heart transplantrecipients. J Am Acad Dermatol 1999; 40 (1): 27–34PubMedCrossRef
44.
España A, Redondo P, Fernández AL, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995; 32: 458–65PubMedCrossRef
45.
Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33: 222–9PubMedCrossRef
46.
Fortina AB, Caforio AL, Piaserico S, et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000; 19 (3): 249–55PubMedCrossRef
47.
Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44 (16): 1172–81PubMed
48.
Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998; 2 (1): 56–63PubMed
49.
Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. BMJ 1988; 296: 13–7PubMedCrossRef
50.
Vitaliano PP, Urbach F. The relative importance of risk factors in nonmelanoma carcinoma. Arch Dermatol 1980; 116: 454–6PubMedCrossRef
51.
52.
Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988; 19: 1045–52PubMedCrossRef
53.
Karakas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. JAMA 1992; 267: 3305–10CrossRef
54.
Armstrong BK, Kricker A. Skin cancer. Dermatol Clin 1995; 13: 583–94PubMed
55.
Blohmé I, Larkö O. Premalignant and malignant lesions in renal transplant recipients. Transplantation 1984; 37: 165–7PubMedCrossRef
56.
Kelly GE, Mahony JF, Sheil AGR, et al. Risk factors for skin carcinogenesis in immunosuppressed kidney transplant recipients. Clin Transplant 1987; 1: 271–7
57.
Taylor AEM, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Demi Venereol (Stockh) 1992; 72: 115–9
58.
Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986; 122: 1288–93PubMedCrossRef
59.
de Jong-Tieben LM, Berkhout RJM, ter Schegget J, et al. The prevalence of human papillomavirus DNA (EV-HPV) in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 2000; 69: 44–9PubMedCrossRef
60.
Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994; 8: 388–95PubMed
61.
Roeger LS, Sheil AGR, Disney APS, et al. Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients. Clin Transplant 1992; 6: 202–11
62.
Shuttleworth D, Marks R, Griffin PJA, et al. Epidermal dysplasia and cyclosporine therapy in renal transplant recipients: a comparison with azathioprine. BrJ Dermatol 1989; 120:551–4CrossRef
63.
Lennard L, Thomas S, Harrington CI, et al. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985; 113:723–9PubMedCrossRef
64.
Jensen P, Hansen S, Moller B, et al. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplant Proc 1999; 31 (1–2): 1120PubMedCrossRef
65.
Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351 (9103): 623–8PubMedCrossRef
66.
Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397 (6719): 530–4PubMedCrossRef
67.
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266: 1865–9PubMedCrossRef
68.
69.
70.
Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet 1995; 346: 799–802PubMedCrossRef
71.
Boshoff C, Whitby D, Hatziioannou T, et al. Kaposi’s-sarcoma-associated herpesvirus in HIV-negative Kaposi’s sarcoma. Lancet 1995; 345: 1043–4PubMedCrossRef
72.
Pfister H, ter Schegget J. Role of HPV in cutaneous premalignant and malignant tumors. Clin Dermatol 1997; 15: 335–437PubMedCrossRef
73.
Harwood CA, McGregor JM, Proby CM, et al. Human papillomavirus and the development of non-melanoma skin cancer. J Clin Pathol 1999; 52 (4): 249–53PubMedCrossRef
74.
Harwood CA, Spink PJ, Surentheran T, et al. Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol 1999; 37 (11): 3545–55PubMed
75.
Orth G. Epidermodysplasia verruciformis. In: Salzman NP, Howley PM, editors. The Papovaviridae, the papillomaviruses. New York: Plenum Publishing Corp, 1987: 199–243CrossRef
76.
Cooper KD, Androphy EJ, Lowy D, et al. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990; 94: 769–76PubMedCrossRef
77.
Pfister H. Human papillomavirus and skin cancer. Semin Cancer Biol 1992; 3: 263–71PubMed
78.
Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312–8PubMedCrossRef
79.
Boxman ILA, Berkhout RJM, Mulder LHC, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108: 712–5PubMedCrossRef
80.
Boxman ILA, Hogewoning A, Mulder LHC, et al. Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts. J Clin Microbiol 1999; 37: 2270–3PubMed
81.
Bouwes Bavinck JN, de Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993; 129: 242–9CrossRef
82.
Rüdlinger R, Smith IW, Bunney MH, et al. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986; 115: 681–92PubMedCrossRef
83.
Dyall-Smith D, Trowell H, Mark A, et al. Cutaneous squamous cell carcinomas and papillomaviruses in renal transplant recipients: a clinical and molecular biological study. J Dermatol Sci 1991; 2: 139–46PubMedCrossRef
84.
Gassenmaier A, Fuchs P, Shell H, et al. Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch Dermatol Res 1986; 278: 219–23PubMedCrossRef
85.
van der Leest RJ, Zachow KR, Ostrow RS, et al. Human papillomavirus heterogeneity in 36 renal transplantrecipients. Arch Dermatol 1987; 123: 354–7PubMedCrossRef
86.
Tieben LM, ter Schegget J, Minnaar RP, et al. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993; 42: 265–80PubMedCrossRef
87.
Soler C, Chardonnet Y, Allibert P, et al. Detection of mucosal human papillomavirus types 6/11 in cutaneous lesions from transplant recipients. J Invest Dermatol 1993; 101: 286–91PubMedCrossRef
88.
Tieben LM, Berkhout RJM, Smits HL, et al. Detection of epidermodysplasia verruciformis-like human papillomavirus types in malignant and premalignant skin lesions of renal transplant recipients. Br J Dermatol 1994; 131: 226–30PubMedCrossRef
89.
Berkhout RJM, Tieben LM, Smits HL, et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995; 33: 690–5PubMed
90.
de Jong-Tieben LM, Berkhout RJM, Smits HL, et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995; 105: 367–71PubMedCrossRef
91.
Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996; 88: 802–11PubMedCrossRef
92.
Höpfl R, Bens G, Wieland U, et al. Human papillomavirus DNA in non-melanoma skin cancers of a renal transplant recipient: detection of a new sequence related to epidermodysplasia verruciformis associated types. J Invest Dermatol 1997; 108: 53–6PubMedCrossRef
93.
Harwood CA, Spink PJ, Surentheran T, et al. Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol 1998; 111: 123–7PubMedCrossRef
94.
Bens G, Wieland U, Hofmann A, et al. Detection of new human papillomavirus sequences in skin lesions of a renal transplant recipient and characterization of one complete genome related to epidermodysplasia verruciformis-associated types. J Gen Virol 1998; 79: 779–87PubMed
95.
Arends MJ, Benton EC, McLaren KM, et al. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. BrJ Cancer 1997; 75: 722–8CrossRef
96.
de Villiers EM, Lavergne D, McLaren K, et al. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 1997; 73: 356–61PubMedCrossRef
97.
McGregor JM, Proby CM. The role of papillomaviruses in human non-melanoma skin cancer. Cancer Surv 1996; 26: 219–36PubMed
98.
Forslund O, Antonsson A, Nordin P, et al. A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol 1999; 80 (9): 2437–43PubMed
99.
Berkhout RJM, Bouwes Bavinck JN, ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre) malignant skin lesions from renal transplant recipients. J Clin Microbiol 2000; 38: 2087–96PubMed
100.
Favre M, Orth G, Majewski S, et al. Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 1998; 110: 311–7PubMedCrossRef
101.
Wieland U, Gross GE, Hofmann A, et al. Novel human papillomavirus (HPV) DNA sequences from recurrent cutaneous and mucosal lesions of a stoma-carrier. J Invest Dermatol 1998; 111: 164–8PubMedCrossRef
102.
Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19 (4): 592–8PubMedCrossRef
103.
Purdie KJ, Pennington J, Proby CM, et al. The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J 1999; 18 (19): 5359–69PubMedCrossRef
104.
Bouwes Bavinck JN, Gissmann L, Claas FHJ, et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993; 151: 1579–86
105.
Kripke ML. Ultraviolet radiation and immunology: something new under the sun: presidential address. Cancer Res 1994; 54: 6102–5PubMed
106.
107.
ten Berge RJM, Schellekens PTA, Surachno S, et al. The influence of therapy with azathioprine and prednisone on the immune system of kidney transplant recipients. Clin Immunol Immunopathol 1981; 21: 20–32PubMedCrossRef
108.
Kelly GE, Sheil AGR, Taylor R. Nonspecific immunological studies in kidney transplant recipients with and without skin cancer. Transplantation 1984; 37: 368–72PubMedCrossRef
109.
Legendre CM, Guttmann RD, Yip GH. Natural killer cell subsets in long-term renal allograft recipients: a phenotypic and functional study. Transplantation 1986; 42: 347–52PubMedCrossRef
110.
Ducloux D, Carron PL, Rebibou JM, et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65 (9): 1270–2PubMedCrossRef
111.
112.
Neefjes JJ, Ploegh HL. Intracellular transport of MHC class II molecules. Immunol Today 1992; 13: 179–84PubMedCrossRef
113.
Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992; 13: 173–9PubMedCrossRef
114.
Czarnecki D, Zalcberg J, Nicholson I, et al. Skin cancer and HLA antigens [letter]. N Engl J Med 1992; 326: 765–6PubMedCrossRef
115.
Czarnecki D, Watkins F, Leahy S, et al. Skin cancers and HLA frequencies in renal transplant recipients. Dermatology 1992; 185:9–11PubMedCrossRef
116.
Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, et al. Skin cancer and HLA antigens [letter]. N Engl J Med 1992; 326: 766CrossRef
117.
Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, et al. HLA-A11-associated resistance to skin cancer in renal-transplant recipients [letter]. N Engl J Med 1990; 323: 1350
118.
Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, et al. On a possible protective effect of HLA-A11 against skin cancer and keratotic skin lesions in renal transplant recipients. J Invest Dermatol 1991; 97: 269–72CrossRef
119.
Bouwes Bavinck JN, Claas FHJ. The role of HLA molecules in the development of skin cancer. Hum Immunol 1994; 41: 173–9CrossRef
120.
Glover MT, Bodmer J, Kennedy LJ, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993; 29A: 520–4PubMedCrossRef
121.
McGregor JM, Reddi G, MacDonald D, et al. HLA-A11 inrenal allograft recipients with skin cancer. J Invest Dermatol 1992; 98: 261–2PubMedCrossRef
122.
Bouwes Bavinck JN, Claas FHJ, Hardie DR, et al. Relation between skin cancer and HLA antigens in renal transplant recipients in Queensland, Australia. J Invest Dermatol 1997; 108:708–11CrossRef
123.
Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Skin cancers in organ transplant recipients. Ann Transplant 1997; 2 (4): 28–32PubMed
124.
Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329: 1147–51PubMedCrossRef
125.
Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basalcell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354 (9180): 723–9PubMedCrossRef
126.
Moriarty M, Dunn J, Darragh A, et al. Etretinate in the treatment of actinic keratosis. Lancet 1982; I: 364–5CrossRef
127.
Anonymous. Retinoids and control of cutaneous malignancy. Lancet 1988; II: 545-6
128.
129.
Kraemer KH, DiGiovanna JJ, Moshel AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633–7PubMedCrossRef
130.
Kelly JW, Sabto J, Gurr FW, et al. Retinoids to prevent skin cancer in organ transplant recipients [letter]. Lancet 1991; 338: 1407PubMedCrossRef
131.
Shuttleworth D, Marks R, Griffin PJA, et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988; 68: 717–24PubMed
132.
Bouwes Bavinck JN, Tieben LM, van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal-transplant recipients; a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933–8
133.
Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59: 714–9PubMedCrossRef
134.
Yuan ZF, Davis A, Macdonald K, et al. Use of acitretin for the skin complications in renal transplant recipients. N Z Med J 1995; 108 (1002): 255–6PubMed
135.
Gibson GE, O’Grady A, Kay EW, et al. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998; 10 (1): 42–7PubMedCrossRef
136.
Mørk NJ, Kolbenstvedt A, Austad J. Efficacy and skeletal side effects of two years’ acitretin treatment. Acta Derm Venereol (Stockh) 1992; 72: 445–8
137.
Euvrard S, Verschoore M, Touraine JL, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992; 340: 48–9PubMedCrossRef
138.
Scholtens REM, van Zuuren EJ, Posma AN. Treatment of recurrent squamous cell carcinoma of the hand in immunosuppressed patients. J Hand Surg 1995; 20A: 73–6
139.
van Zuuren EJ, Posma AN, Scholtens REM, et al. Resurfacing of the hand as treatment and prevention of multiple skin cancers in renal transplant recipients. J Am Acad Dermatol 1994; 31:760–4PubMedCrossRef
Metadata
Title
Skin Cancer Risk Associated with Immunosuppressive Therapy in Organ Transplant Recipients
Epidemiology and Proposed Mechanisms
Authors
Iris Kuijken
Jan N. Bouwes Bavinck
Publication date
01-11-2000
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 5/2000
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200014050-00004

Other articles of this Issue 5/2000

BioDrugs 5/2000 Go to the issue

Disease Management

Chronic Rejection of the Liver

Disease Management

Interleukin-2 in Cancer Therapy

Review Article

The Cost of Crohn’s Disease

Leading Article

Rotavirus Vaccine